All In MedTech

Device Trial Radar · NCT07359547

Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt

Minimally Invasive Bleb-Forming Surgical Approaches for Treating Primary Open-Angle Glaucoma: A Randomized Controlled Trial Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 166 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

166

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Jan 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University Hospital, Bonn; Hospital de Santa Maria, Lisbon
First posted
Jan 22, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized controlled clinical trial is to learn whether two minimally invasive bleb-forming glaucoma implants can effectively treat adult patients with open-angle glaucoma who require surgical lowering of intraocular pressure (IOP). Specifically, the study evaluates whether the PRESERFLO™ MicroShunt is at least as effective as the XEN®-63 Gel Stent in reducing IOP after surgery.  The main questions it aims to answer are: * Does the PRESERFLO™ MicroShunt provide IOP reduction at 12 months that is non-inferior to the XEN®-63 Gel Stent? * How do the two devices compare over 24 months with respect to medication reduction, need for additional glaucoma procedures, complications, and preservation of visual function and ocular structures? Participants will: * Be randomly assigned (1:1) to receive either the XEN®-63 Gel Stent or the PRESERFLO™ MicroShunt during a single glaucoma surgery. * Attend scheduled follow-up visits over 24 months for eye-pressure measurements, vision testing, visual-field testing, OCT imaging, endothelial-cell counts, and safety assessments. * Receive standard postoperative care and report any complications or additional treatments during the study period.

Conditions

  • GLAUCOMA 1, OPEN ANGLE, D (Disorder)

Interventions

  • XEN®-63 Gel StentDevice

    The XEN®-63 Gel Stent is a hydrophilic gel implant made of cross-linked, purified collagen (gelatin). This devices bypasses the trabecular meshwork and lower eye pressure via a subconjunctival filtering bleb, aided by intra-operative mitomycin C to reduce scarring. It has already been approved for the European market and therefore bear the CE mark.

  • PRESERFLO™ MicroShuntDevice

    The PRESERFLO™ MicroShunt is a SIBS-polymer microshunt. This devices bypasses the trabecular meshwork and lower eye pressure via a subconjunctival filtering bleb, aided by intra-operative mitomycin C to reduce scarring. It has already been approved for the European market and therefore bear the CE mark.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular pressureTime frame: 1 year

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • University Hospitals UZ Leuven

    Leuven, Vlaams-brabant, Belgium · Recruiting

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, Germany · Recruiting

  • ULS Santa Maria

    Lisbon, Lisbon District, Portugal · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.